Latest News
EDHL Stock Surges on Heavy Volume, Retail Momentum Drives Micro-Cap Rally
EDHL stock surged over 200% on heavy volume, driven by retail momentum in a micro-cap with a thin float, despite weak financials and no new corporate news.
Virgin Galactic Shares Surge 20% After $30.5M Debt-for-Equity Swap
Virgin Galactic shares soared 20% to $5.67 after the company redeemed $30.5 million of 9.80% First Lien Notes by issuing 6.73 million shares, easing near-term debt pressure and boosting liquidity ahead of planned commercial spaceflight in late 2026, even as volatility and dilution concerns persist.
Adobe Plunges Ahead of Q2 Earnings as AI Fears Mount
Adobe shares fell 4.6% to $222.66 ahead of Q2 earnings, with options signaling an 8.5% swing that could push ADBE near 2019 lows amid AI fears and CEO transition.
Dollarama Shares Jump 8% as Q1 Sales and Profit Top Estimates
Dollarama shares surged 8.11% after beating Q1 sales and profit estimates, with Canadian comparable sales up 5.6% and strong international growth. The company maintained its fiscal 2027 guidance and declared a $0.12 dividend.
Uber Stock Slips Amid NYC Regulatory Battle Over Driver Deactivations
Uber shares dropped Thursday as investors reacted to a legal battle over New York City's Local Law 52, which limits ride-hailing companies' ability to deactivate drivers without just cause.
PureCycle Stock Tumbles 16% on $395M Capital Raise, Dilution Concerns
PureCycle Technologies shares dropped 16% after a $395 million capital raise, including 17.66 million new shares and $250 million in convertible notes, sparking dilution concerns.
Pfizer Stock Rises on RBC Upgrade Despite German Drug-Pricing Threat
Pfizer shares rose 2.7% to $26.28 after RBC Capital upgraded the stock to Sector Perform, citing improved risk-reward. Meanwhile, a Reuters report flags German drug-pricing policy risks that could affect investments.
Theriva Biologics Surges on Phase 1 Cancer Data, But Risks Remain
TOVX surged 74.6% on Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump is not based on approval or revenue.
Trulieve Debuts on NYSE, Launches $50M Buyback Amid Policy Shifts
Trulieve started trading on the NYSE as TRLV, authorized a $50 million buyback, and closed its first day at $11.50. Investors eye liquidity gains amid cannabis rescheduling.
Propanc Biopharma Soars After Announcing $5M Stock Buyback
Propanc Biopharma shares skyrocketed after the company authorized a $5 million stock buyback, surpassing its entire market value. Investors now watch for progress on its cancer drug PRP.